| SEC Form 4 |
|------------|
|------------|

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL

| OMB Number: | B Number: 3235-0287 | | | | | | | |
|--------------------------|---------------------|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | 01 000 | | vestinei | 11 001 | ipany Act of 13 | 40 | | | | |
|--|---------|------------------------------------|-----------------|--|---|----------|--------|---|---|--|--|-----------------|------------|
| 1. Name and Address of Reporting Person [*] Smith Cynthia | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Akebia Therapeutics, Inc.</u> [AKBA] | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | |
| (Last) (First) (Middle) C/O AKEBIA THERAPEUTICS, INC | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/05/2020 | | | | | | | Officer (give title below) | Other below) | (specify |
| 245 FIRST STREET | | | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | 6. Indiv Line) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | |
| (Street) CAMBRIDGE | MA | 02142 | | | | | | | | X | Form filed by One Form filed by Mor Person | | |
| (City) | (State) | (Zip) | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | |
| Date | | 2. Transacti Date (Month/Day | Execution Date, | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (/ Disposed Of (D) (Instr. 3 | | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | | | 06/05/20 | 020 | | Α | | 13,700 ⁽¹⁾ | A | \$0.00 | 42,400 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 8. Price of 9. Number of 11. Nature 10. 2. Conversion Ownership Date Execution Date. Transaction Derivative Expiration Date of Securities Derivative derivative of Indirect Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) if any (Month/Day/Year) or Exercise Price of Derivative (Month/Day/Year) Underlying Derivative Security (Instr. 3 and 4) Form: Direct (D) or Indirect Security (Instr. 3) Code (Instr. 8) (Month/Day/Year) Security (Instr. 5) Securities Beneficially Beneficial Ownership (Instr. 4) Owned Following Security (I) (Instr. 4) Reported Transaction(s) Amount (Instr. 4) Number Date Expiration of Shares Code ν (A) (D) Exercisable Date Title Stock Option (Right to Commo 06/05/2020 20,100⁽³⁾ \$11.96 A 06/05/2021 06/05/2030 20,100 \$0.00 20,100 D Stock buy)

S⁽²⁾

4,567

Explanation of Responses:

Common Stock

1. The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

2. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019.

3. Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

Remarks:

/s/ Nicole R. Hadas, attorney-in-06/09/2020

fact for Cynthia Smith

** Signature of Reporting Person Date

\$12.1

D

37,833

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

06/08/2020

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.